Study ID: Merck Shingles Vaccine V212-011-00
Description:

A Phase III, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of V212 in Adults with Solid Tumor or Hematologic Malignancy

Location:
Sioux Falls Region,Fargo Region,Bismarck Region
Principal Investigator:
Miroslaw Mazurczak MD
Disease:
Cancer Prevention
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list